Please login to the form below

Not currently logged in
Email:
Password:

Robert Simon to lead regulatory affairs at Threshold

Will oversee approval process for cancer treatment TH-302 in development with Merck KGaA

Robert Simon has joined Threshold Pharmaceuticals as its senior VP of regulatory affairs and will oversee regulatory activities for investigational cancer treatment TH-302, which the company is developing in partnership with Merck KGaA.

Threshold wants to tap into Simon's 28 years of experience in drug development and regulatory affairs as it attempts to launch the drug in several areas of oncology, including soft tissue sarcoma and pancreatic cancer.

“Bob has played key roles in the successful registration of more than a dozen new drug applications worldwide, including the established oncology drugs, Tarceva and Taxol," said Dr Tillman Pearce, chief medical officer of Threshold.

Prior to joining Threshold, Simon spent almost a decade at OSI Pharmaceuticals, in roles that included VP of global regulatory affairs and chemistry manufacturing controls (CMC) for oncology, as well as executive VP.

He has also spent time at Gilead as VP of global regulatory affairs following a 13-year spell at Bristol-Myers Squibb in several regulatory affairs positions.

"I am looking forward to working with the Threshold team in developing the first hypoxia-targeted cancer drug, TH-302," said Simon.

26th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics